Cargando…
BRAF突变晚期NSCLC的靶向和免疫治疗研究进展
With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without dr...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560979/ https://www.ncbi.nlm.nih.gov/pubmed/34696543 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.29 |